Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly paid $140 million upfront for the right to buy Radionetics Oncology for $1 billion, continuing its push into radiopharmaceutical therapy. Radionetics…
Eli Lilly is paying $140 million for an exclusive option to acquire Radionetics Oncology for $1 billion, expanding its radiopharmaceutical footprint beyond…
Eli Lilly and Radionetics Oncology announced a strategic agreement under which Lilly holds an exclusive option to acquire Radionetics for $1 billion, having…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Radionetics Oncology entered strategic agreement with Eli Lilly under which Radionetics receives $140M upfront cash payment and Lilly obtains exclusive right to acquire Radionetics for $1B upon exercise. Deal builds on Lilly's radiopharmaceutical platform following 2023 POINT Biopharma acquisition. Top-25 pharma buyer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Radionetics Oncology Inc. (this deal) | 2024 | $1.1B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2024 deals · Eli Lilly and Company deals · Oncology deals